Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 88.6%

Neg 0% Neu 0% Pos 88.6%

Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.